In this Pharmaceutical Executive video interview, Panna Sharma, CEO, Lantern Pharma, explains which specific endpoints they’ll be looking at in the Phase I trial to assess LP-284’s potential efficacy and how the insights gained will be fed back into RADR®
Assessing LP-284 with RADR for NHL and Other Targeted Cancers
Estimated read time
1 min read
+ There are no comments
Add yours